Tubulis GmbH

📍 Munich, Germany👥 55 employees💰 Last funded Mar 2024
Biotechnology Research🌐 tubulis.com
Website LinkedIn
Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.
5
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

5 investors
All
Early stage
Mid stage
Late stage
Investor geography3 countries
Germany
3
United States
1
Netherlands
1
Investor activity2020–2024 · investors recorded per year
202022023120242
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Tubulis GmbH?
Tubulis GmbH has 5 investors on record on gritt.io.
When did Tubulis GmbH last raise funding?
The most recent investment in Tubulis GmbH recorded on gritt.io was in March 2024.
What industry is Tubulis GmbH in?
Tubulis GmbH operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Tubulis GmbH based?
Tubulis GmbH is headquartered in Munich, Germany.